Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Yearly Archives: 2011

Aegis Therapeutics Awarded Patent for Parathyroid Hormone (PTH) Peptide Drug Formulations Suitable for Metered Nasal Spray, Oral, and Injectable Delivery

SAN DIEGO, CA  December 13, 2011/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,076,290 providing broad protection for stabilized formulations of parathyroid hormone (PTH) and PTH peptide analogs such as PTH 1-34 suitable for all routes of administration including the non-invasive metered nasal spray delivery route or injection. Examples […]

Aegis Therapeutics Awarded Patent for GLP-1 Peptide Drug Formulations Suitable for Metered Nasal Spray and Oral Delivery

SAN DIEGO, CA  August 16, 2011/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 7,998,927 providing broad protection for stabilized formulations of GLP-1 peptide analogs suitable for all routes of administration including the non-invasive oral or metered nasal spray delivery routes, or injection. Examples of GLP-1 analogs include Novo Nordisk’s […]

Albany Medical College and Aegis Therapeutics Form Partnership to Advance Leading Edge Oral Breast Cancer Drug Candidate Derived From a Natural Pregnancy Associated Protein

SAN DIEGO, CA  May 10, 2011 (Marketwire)– Scientists at Albany Medical College have developed a potential new breast cancer drug based on a naturally occurring protein of human pregnancy.   The drug inhibits the growth of cancer cells more effectively in preclinical studies than does the leading anti-breast cancer drug tamoxifen, and does not cause the […]

Oral Bioavailability of Octreotide Using Aegis’ Intravail® Formulation Technology Surpasses That Obtained by Injection

SAN DIEGO, CA April 13, 2011 – Scientists at Albany Medical College and Aegis Therapeutics report that oral delivery of the peptide drug octreotide, in the presence of the absorption enhancer Intravail®, achieves systemic bioavailability that exceeds that achieved by subcutaneous injection. This second example of unsurpassed oral bioavailability of a peptide drug is reported […]